Standard-Dose DOACs Outperform Warfarin Even More Strongly in Asian AFib Patients
A 71,000-patient meta-analysis finds standard-dose DOACs cut stroke and bleeding risk far more in Asian than non-Asian atrial fibrillation patients.
Summary
A large patient-level meta-analysis pooling data from four major randomized trials compared blood thinners in over 71,000 atrial fibrillation patients, separating results by Asian versus non-Asian race. Asian patients on warfarin fared worse across nearly every outcome — more strokes, more bleeding, and poorer time in therapeutic range. Switching to standard-dose direct oral anticoagulants (DOACs) like apixaban or rivaroxaban produced dramatically larger benefits in Asians: a 35% reduction in stroke risk and 38% reduction in major bleeding, compared to roughly 14% and 9% reductions in non-Asians. Importantly, standard-dose DOACs did not raise gastrointestinal bleeding risk in Asian patients, unlike in non-Asians. Lower-dose DOACs were actually harmful in Asians, significantly increasing stroke risk. The findings strongly support using standard-dose DOACs as the preferred anticoagulation strategy for Asian patients with atrial fibrillation.
Detailed Summary
Atrial fibrillation is the most common cardiac arrhythmia worldwide, and anticoagulation is the cornerstone of stroke prevention. Yet most large trials enrolled predominantly non-Asian populations, leaving clinicians uncertain whether treatment effects differ meaningfully by race. This meta-analysis addresses that gap with the largest race-stratified dataset to date.
Researchers analyzed patient-level data from the COMBINE AF collaboration, which pooled all four pivotal DOAC-versus-warfarin randomized trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48). Of 71,683 total patients, 10,212 were Asian. At baseline, Asian patients were younger, lighter, had worse kidney function, and had higher rates of prior stroke or TIA — a profile suggesting elevated baseline risk.
On warfarin, Asian patients achieved lower time in therapeutic range (57.7% vs. 66.2%) and suffered significantly higher rates of stroke, major bleeding, intracranial hemorrhage, and gastrointestinal bleeding compared to non-Asians. When switched to standard-dose DOACs, Asians experienced substantially greater relative risk reductions than non-Asians for stroke/systemic embolism (HR 0.65 vs. 0.86), major bleeding (HR 0.62 vs. 0.91), and the composite net clinical outcome — with statistically significant interaction terms confirming the differential benefit.
A particularly notable finding: standard-dose DOACs did not increase gastrointestinal bleeding in Asian patients, in contrast to a 41% increase seen in non-Asians. This removes a commonly cited concern about DOAC use in this population. Across varying body weights and kidney function levels within the Asian subgroup, standard-dose DOACs consistently outperformed warfarin.
Critically, lower-dose DOACs were associated with a 57% higher stroke risk compared to standard doses in Asians, suggesting that dose reduction strategies intended to minimize bleeding may inadvertently increase thromboembolic harm. Clinicians should default to standard dosing unless specific pharmacokinetic criteria are met. This analysis provides the strongest evidence yet for race-informed anticoagulation decision-making in atrial fibrillation.
Key Findings
- Standard-dose DOACs reduced stroke risk by 35% in Asian AFib patients vs. only 14% in non-Asians.
- Major bleeding was cut 38% by standard-dose DOACs in Asians, compared to just 9% in non-Asians.
- Standard-dose DOACs did NOT increase gastrointestinal bleeding in Asian patients, unlike non-Asians.
- Lower-dose DOACs raised stroke risk by 57% compared to standard doses in Asian patients.
- Asian patients on warfarin had worse therapeutic control and higher rates of every adverse outcome.
Methodology
Patient-level meta-analysis of four pivotal randomized controlled trials (RE-LY, ROCKET-AF, ARISTOTLE, ENGAGE AF-TIMI 48) pooled through the COMBINE AF collaboration, totaling 71,683 patients including 10,212 Asians. Outcomes were compared using adjusted hazard ratios with interaction testing between race and treatment assignment. Body weight and creatinine clearance subgroup analyses were also performed within the Asian cohort.
Study Limitations
Summary is based on the abstract only, as the full text is not open access. Race classification methodology and how Asian subgroups were defined across four different trials is not detailed in the abstract. Residual confounding from baseline differences between Asian and non-Asian patients cannot be fully excluded despite adjustment.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.